ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin
plus initiatives to improve compliance. If the subject does not reach the EAS LDL-C treatment
goal at week 12, rosuvastatin will be titrated from 10mg to 20mg.